Al Amyloidosis Epidemiology Forecast Insight

DelveInsight’s ‘AL Amyloidosis – Epidemiology Forecast—2030’ report delivers an in-depth understanding of AL Amyloidosis historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

AL Amyloidosis Disease Understanding

Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis. It starts in the bone marrow, the soft tissue inside the bones that makes blood-forming cells, including cells that create antibodies to fight infections. These cells can grow abnormally, causing an excess type of protein called light chains, which clump together and form amyloid deposits in major organs. Progressive organ dysfunction (Heart, Kidney, Liver, etc.) is driven by amyloid deposition, and the risk of early death is the hallmark of severe AL amyloidosis.

AL Amyloidosis Epidemiology

The AL Amyloidosis epidemiology division provides insights about the historical and incident patient pool, along with the forecasted trend for all seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.

 

Key Findings

The total incident cases of AL Amyloidosis patients in the 7MM are increasing during the study period, i.e., 2018–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted AL Amyloidosis symptoms epidemiology segmented as the total Incident cases of AL Amyloidosis, gender-specific cases of AL Amyloidosis, and age-specific cases of AL Amyloidosis. The report includes the incident cases of AL Amyloidosis in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise AL Amyloidosis Epidemiology

The epidemiology segment also provides AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The Incident cases of AL Amyloidosis associated in 7MM countries were 8,647 in 2020.
  • As per the estimates, the United States has the largest prevalent population of AL Amyloidosis
  • Among the EU5 countries, Germany had the highest prevalent cases of AL Amyloidosis, followed by France. On the other hand, Spain had the lowest prevalent cases at 413 in 2020.

Scope of the Report

  • The AL Amyloidosis report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The AL Amyloidosis Epidemiology Report and Model provide an overview of AL Amyloidosis’ risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into AL Amyloidosis’ historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of AL Amyloidosis.
  • The report provides the segmentation of the AL Amyloidosis epidemiology by the Incidence Cases of AL Amyloidosis in 7MM.
  • The report provides the AL Amyloidosis epidemiology segmentation by gender-specific cases of AL Amyloidosis in 7MM.
  • The report provides the AL Amyloidosis epidemiology segmentation by age-specific cases of AL Amyloidosis in 7MM.

Report Highlights

  • 10-year Forecast of AL Amyloidosis epidemiology
  • 7MM Coverage
  • Incidence Cases of AL Amyloidosis
  • Gender-specific cases of AL Amyloidosis
  • Age-specific Cases of AL Amyloidosis

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the change in the patient population in AL Amyloidosis during the forecast period (2018–2030)?
  • What are the key findings of the AL Amyloidosis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of AL Amyloidosis patients across the 7MM during the forecast period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2018–2030)?
  • What are the disease risks, burden, and unmet needs of AL Amyloidosis market?
  • What are the current treatment patterns for AL Amyloidosis?

Reasons to buy

The AL Amyloidosis epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global AL Amyloidosis market.
  • Quantify patient populations in the global AL Amyloidosis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for AL Amyloidosis therapeutics in each market covered.
  • Understand the magnitude of the AL Amyloidosis population by its incidence.
  • Understand the magnitude of the AL Amyloidosis population by its Gender-specific cases.
  • Understand the magnitude of the AL Amyloidosis population by its Age-specific cases.
  • The AL Amyloidosis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The AL Amyloidosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. AL Amyloidosis Market Overview at a Glance

3.1. Market Share (%) Distribution of AL Amyloidosis in 2018

3.2. Market Share (%) Distribution of AL Amyloidosis in 2030

4. Executive Summary of AL Amyloidosis

5. Disease Background and Overview

5.1. Introduction

5.2. Types of Amyloidosis

5.3. Clinical Manifestations

5.4. Signs and Symptoms

5.5. Risk Factors

5.6. Pathogenesis

5.7. Staging

5.8. Recurrent AL Amyloidosis

5.9. Diagnosis

5.9.1. Diagnostic Guidelines

5.10. Differential Diagnosis

5.11. Treatment and Management

5.12. Treatment Guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incident Population of AL Amyloidosis

6.3. Epidemiology of AL Amyloidosis

6.4. The United States

6.4.1. Incident Cases of AL Amyloidosis in the United States

6.4.2. Gender-specific cases of AL Amyloidosis in the United States

6.4.3. Age-specific Cases of AL Amyloidosis in the United States

6.5. EU-5

6.5.1. Total Incident Cases of AL Amyloidosis in EU-5

6.5.2. Gender-specific Cases of AL Amyloidosis in EU-5

6.5.3. Age-specific Cases of AL Amyloidosis in EU-5

6.6. Japan

6.6.1. Incident Cases of AL Amyloidosis in Japan

6.6.2. Gender-specific Cases of AL Amyloidosis in Japan

6.6.3. Age-specific Cases of AL Amyloidosis

7. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

Table 1: Summary of AL Amyloidosis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Staging of AL Amyloidosis

Table 3: Guidelines on the diagnosis and investigation of AL amyloidosis in the UK

Table 4: Supportive therapy in AL amyloidosis

Table 5: Guidelines on the management of AL amyloidosis in the UK

Table 6: Total Incident Population of AL Amyloidosis in 7MM (2018–2030)

Table 7: Incident Cases of AL Amyloidosis in the United States (2018–2030)

Table 8: Gender-specific cases of AL Amyloidosis in the United States (2018–2030)

Table 9: Age-specific Cases of AL Amyloidosis in the United States (2018–2030)

Table 10: Total Incident Cases of AL Amyloidosis in EU-5 (2018–2030)

Table 11: Gender-specific Cases of AL Amyloidosis in EU-5 (2018–2030)

Table 12: Age-specific Cases of AL Amyloidosis in EU-5 (2018–2030)

Table 13: Incident Cases of AL Amyloidosis in Japan (2018–2030)

Table 14: Gender-specific cases of AL Amyloidosis in Japan (2018–2030)

Table 15: Age-specific Cases of AL Amyloidosis in Japan (2018–2030)

List of Figures

Figure 1: Common forms of systemic amyloidosis

Figure 2: Clinical Manifestations in AL Amyloidosis

Figure 3: Mechanisms involved in the pathogenesis of AL Amyloidosis

Figure 4: Clinical reasoning for starting second-line therapy after initial response to frontline therapy in ALA

Figure 5: Algorithm for the diagnosis of AL Amyloidosis

Figure 6: Current treatment algorithm in light-chain amyloidosis

Figure 7: Total Incident Population of AL Amyloidosis in 7MM (2018–2030)

Figure 8: Incident Cases of AL Amyloidosis in the United States (2018–2030)

Figure 9: Gender-specific cases of AL Amyloidosis in the United States (2018–2030)

Figure 10: Age-specific Cases of AL Amyloidosis in the United States (2018–2030)

Figure 11: Total Incident Cases of AL Amyloidosis in EU-5 (2018–2030)

Figure 12: Gender-specific Cases of AL Amyloidosis in EU-5 (2018–2030)

Figure 13: Age-specific Cases of AL Amyloidosis in EU-5 (2018–2030)

Figure 14: Incident Cases of AL Amyloidosis in Japan (2018–2030)

Figure 15: Gender-specific cases of AL Amyloidosis in Japan (2018–2030)

Figure 16: Age-specific Cases of AL Amyloidosis in Japan (2018–2030)

Forward to Friend

Need A Quote